BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37745365)

  • 1. A clinicogenomic model including GARD predicts outcome for radiation treated patients with HPV+ oropharyngeal squamous cell carcinoma.
    Ho E; De Cecco L; Cavalieri S; Sedor G; Hoebers F; Brakenhoff RH; Scheckenbach K; Poli T; Yang K; Scarborough JA; Campbell S; Koyfman S; Eschrich SA; Caudell JJ; Kattan MW; Licitra L; Torres-Roca JF; Scott JG
    medRxiv; 2023 Sep; ():. PubMed ID: 37745365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma.
    Gabani P; Lin AJ; Barnes J; Oppelt P; Adkins DR; Rich JT; Zevallos JP; Daly MD; Gay HA; Thorstad WL
    Radiother Oncol; 2019 May; 134():81-88. PubMed ID: 31005228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of concomitant chemoradiotherapy in AJCC 7
    Lu DJ; Luu M; Nguyen AT; Shiao SL; Scher K; Mita A; Anderson E; Clair JM; Ho AS; Zumsteg ZS
    Oral Oncol; 2020 Nov; 110():104882. PubMed ID: 32650257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base.
    Amini A; Jasem J; Jones BL; Robin TP; McDermott JD; Bhatia S; Raben D; Jimeno A; Bowles DW; Karam SD
    Oral Oncol; 2016 May; 56():1-7. PubMed ID: 27086480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined chemoradiotherapy showed improved outcome with early-stage HPV-positive oropharyngeal cancers.
    Lu XJD; Jackson E; Chew J; Nguyen S; Wu J; Poh CF; Prisman E
    BMC Cancer; 2022 May; 22(1):513. PubMed ID: 35525912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
    Shiao JC; Holt D; Ladbury C; Gao D; Jones B; Karam SD; Amini A
    Oral Oncol; 2022 Jul; 130():105907. PubMed ID: 35605559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and genomic characterization of chemoradiation-resistant HPV-positive oropharyngeal squamous cell carcinoma.
    Guo T; Zamuner F; Ting S; Chen L; Rooper L; Tamayo P; Fakhry C; Gaykalova D; Mehra R
    Front Oncol; 2024; 14():1336577. PubMed ID: 38505587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis.
    Scott JG; Sedor G; Ellsworth P; Scarborough JA; Ahmed KA; Oliver DE; Eschrich SA; Kattan MW; Torres-Roca JF
    Lancet Oncol; 2021 Sep; 22(9):1221-1229. PubMed ID: 34363761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) Staging for Selected and Nonselected Oropharyngeal Squamous Cell Carcinomas.
    Vijayvargiya P; Trivedi S; Rupji M; Song H; Liu Y; Jiang R; Kaka AS; Chen GZ; Stokes W; Steuer C; Shin DM; Beitler JJ; Patel MR; Aiken A; Saba NF
    Oncologist; 2022 Feb; 27(1):48-56. PubMed ID: 35305095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?
    Yoshida EJ; Luu M; Mallen-St Clair J; Mita AC; Scher KS; Lu DJ; Nguyen AT; Shiao SL; Ho AS; Zumsteg ZS
    Cancer; 2020 Jan; 126(1):58-66. PubMed ID: 31536144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma.
    Howard J; Dwivedi RC; Masterson L; Kothari P; Quon H; Holsinger FC
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012939. PubMed ID: 30550641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practice patterns and outcomes following radiation dose de-escalation for oropharyngeal cancer.
    White R; Abel S; Hasan S; Verma V; Greenberg L; Colonias A; Wegner RE
    Laryngoscope; 2020 Apr; 130(4):E171-E176. PubMed ID: 31120601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of AJCC/UICC 8th Edition New Staging Rules in Oropharyngeal Squamous Cell Carcinoma.
    Würdemann N; Wagner S; Sharma SJ; Prigge ES; Reuschenbach M; Gattenlöhner S; Klussmann JP; Wittekindt C
    Front Oncol; 2017; 7():129. PubMed ID: 28713770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    An Y; Park HS; Kelly JR; Stahl JM; Yarbrough WG; Burtness BA; Contessa JN; Decker RH; Koshy M; Husain ZA
    Cancer; 2017 Jul; 123(14):2762-2772. PubMed ID: 28323338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma.
    Elhalawani H; Mohamed ASR; Elgohari B; Lin TA; Sikora AG; Lai SY; Abusaif A; Phan J; Morrison WH; Gunn GB; Rosenthal DI; Garden AS; Fuller CD; Sandulache VC
    BMC Cancer; 2020 Sep; 20(1):912. PubMed ID: 32967643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Females Have Worse Overall and Disease-Specific Survival in Human Papillomavirus-Negative Oropharyngeal Squamous Cell Carcinoma.
    Hunter WP; Harris JA; Lee CC; Cheng AC; Peacock ZS
    J Oral Maxillofac Surg; 2022 Jul; 80(7):1260-1271. PubMed ID: 35469827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.
    Freitag J; Wald T; Kuhnt T; Gradistanac T; Kolb M; Dietz A; Wiegand S; Wichmann G
    Cancer; 2020 Jan; 126(9):1856-1872. PubMed ID: 32032442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Human Papilloma Virus and Lifestyle Factors in Overall Survival of Patients with Oropharyngeal Squamous Cell Carcinoma.
    Nishikawa D; Hanai N; Ozawa T; Kitahara T; Hasegawa Y
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification.
    Zeng PYF; Cecchini MJ; Barrett JW; Shammas-Toma M; De Cecco L; Serafini MS; Cavalieri S; Licitra L; Hoebers F; Brakenhoff RH; Leemans CR; Scheckenbach K; Poli T; Wang X; Liu X; Laxague F; Prisman E; Poh C; Bose P; Dort JC; Shaikh MH; Ryan SEB; Dawson A; Khan MI; Howlett CJ; Stecho W; Plantinga P; Daniela da Silva S; Hier M; Khan H; MacNeil D; Mendez A; Yoo J; Fung K; Lang P; Winquist E; Palma DA; Ziai H; Amelio AL; Li SS; Boutros PC; Mymryk JS; Nichols AC
    EBioMedicine; 2022 Dec; 86():104373. PubMed ID: 36442320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
    Scott JG; Berglund A; Schell MJ; Mihaylov I; Fulp WJ; Yue B; Welsh E; Caudell JJ; Ahmed K; Strom TS; Mellon E; Venkat P; Johnstone P; Foekens J; Lee J; Moros E; Dalton WS; Eschrich SA; McLeod H; Harrison LB; Torres-Roca JF
    Lancet Oncol; 2017 Feb; 18(2):202-211. PubMed ID: 27993569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.